References
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA:
a cancer journal for clinicians. 2022;72(1):7-33.
2. Zheng R, Zhang S, Zeng H, Wang S, Sun K, et al. Cancer incidence and
mortality in China, 2016. J Nat Cancer Cent. 2022;2(1):1-9.
3. Guan H, Wang C, Chen C, Han S, Zhao Z. Cost-Effectiveness of 12
First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in
the United Kingdom and China. Frontiers in Oncology. 2022;12:819674.
4. Shu Y, Zhang Q, He X, Chen L. Cost-effectiveness analysis of
gefitinib plus chemotherapy versus gefitinib alone for advanced
non-small-cell lung cancer with EGFR mutations in China. Cancer
Management and Research. 2021;13:8297.
5. Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, et al. Phase I
pharmacokinetic trial of the selective oral epidermal growth factor
receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in
Japanese patients with solid malignant tumors. Annals of oncology.
2003;14(6):922-930.
6. Cantarini MV, McFarquhar T, Smith RP, Bailey C, Marshall AL. Relative
bioavailability and safety profile of gefitinib administered as a tablet
or as a dispersion preparation via drink or nasogastric tube: results of
a randomized, open-label, three-period crossover study in healthy
volunteers. Clinical therapeutics. 2004;26(10):1630-1636.
7. Cantarini MV, Bailey CJ, Collins B, Smith RP. The relative
bioavailability of gefitinib administered by granular formulation.
Cancer chemotherapy and pharmacology. 2008;62(2):203-208.
8. P D, Li P, Liu H, Zhao R, Zhao Z, et al. Open-Label, Randomized,
Single-Dose, 2-Period, 2-Sequence Crossover, Comparative Pharmacokinetic
Study to Evaluate Bioequivalence of 2 Oral Formulations of Olanzapine
Under Fasting and Fed Conditions. Clin Pharmacol Drug Dev.
2019;9(5):621-628.
9. An Z, Wang X, Li P, He J, Liu L. Exploring the metabolic
characteristics and pharmacokinetic variation of paroxetine in healthy
volunteers using a pharmacometabonomic approach. Journal of
Pharmaceutical and Biomedical Analysis. 2021:114224.
10. Culy CR, Faulds D. Gefitinib. Drugs. 2002;62(15):2237-2248.
11. Swaisland H, Laight A, Stafford L, Jones H, Morris C, et al.
Pharmacokinetics and tolerability of the orally active selective
epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in
healthy volunteers. Clinical pharmacokinetics. 2001;40(4):297-306.
12. Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in
bioavailability of small molecular tyrosine kinase inhibitors. Cancer
Treatment Reviews. 2015;41(5):412-422.
13. Zhang H, Li Q, Zhu X, Wu M, Li C, et al. Association of variability
and pharmacogenomics with bioequivalence of gefitinib in healthy male
subjects. Frontiers in pharmacology. 2018;9:849.
14. Davit BM, Kanfer I, Tsang YC, Cardot J-M. BCS biowaivers:
similarities and differences among EMA, FDA, and WHO requirements. The
AAPS journal. 2016;18(3):612-618.
15. Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, et al.
Single-dose clinical pharmacokinetic studies of gefitinib. Clinical
pharmacokinetics. 2005;44(11):1165-1177.
16. Moon SJ, Kim Y, Jeon J-Y, Park S-J, Kwak Y-G, et al. Pharmacokinetic
properties and bioequivalence of gefitinib 250 mg in healthy Korean male
subjects. Translational and Clinical Pharmacology. 2021;29(3):171.
17. Bergman E, Forsell P, Persson EM, Knutson L, Dickinson P, et al.
Pharmacokinetics of gefitinib in humans: the influence of
gastrointestinal factors. International journal of pharmaceutics.
2007;341(1-2):134-142.
18. Wan Z, Guo L, Li P, Zhao Z, Xu B, et al. Determinants of gefitinib
pharmacokinetics in healthy Chinese male subjects: a pharmacogenomic
study of cytochrome p450 enzymes and transporters. Journal of Clinical
Pharmacy and Therapeutics. 2020;45(5):1159-1167.